Company: TBPH
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001104659-25-033819
Chunk: 51

Company: Theravance Biopharma, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 51
---
2024 base salaries were as follows: $1,047,431 for Mr. Winningham, $463,500 for Mr. Sawaf and $482,040 for Mr. Grimaud, reflecting no increase from 2023 for Mr. Winningham and 3% increases from 2023 for Mr. Sawaf and Mr. Grimaud. In addition, Mr. Winningham entered into a share purchase agreement to use approximately 20% of his after-tax 2024 base salary to periodically purchase our ordinary shares at the closing price on each purchase date. We believe that successful execution against our corporate goals is the best way to enhance shareholder value. Accordingly, each of our named executive officers is eligible for an annual cash bonus under our company-wide bonus program, which is designed to reward achievement of key corporate goals established by our board of directors as well as individual performance. Each participant in our company-wide bonus program, including our named executive officers, has a target bonus stated as a percentage of annual base salary for the year. For 2024, target bonus percentages remained consistent with the prior year and were 50% of annual base salary for senior vice presidents and 60% of annual base salary for our Chief Executive Officer. In determining individual bonuses for our named executive officers, our compensation committee first assesses achievement of the corporate goals to establish the size of the company-wide bonus pool. Then each individual officer’s bonus may be increased or decreased based on a subjective assessment of individual performance, up to a maximum achievement of 200% of the target. The corporate goals under the bonus program are established by our board of directors annually and are focused on strategic objectives that advance our mission and are intended to create long-term value for our shareholders. We typically set more goals than we reasonably believe we can accomplish in a given time frame to drive the leadership team’s performance and set a tone of high achievement. Our 2024 corporate goals highlighted key commercial, development, and corporate objectives intended to drive performance, provide a consistent direction, and align employee focus and effort with our board of directors’ vision for long-term and short-term value creation and our core purpose of developing medicines that make a 33

TABLE OF CONTENTS

difference in the lives of patients. In 2024, the bonus program goals were divided into three categories — commercial, development, and corporate—with weighting for each category varying based on individual employee function. At the end of the year, our compensation committee reviewed performance against the goals and determined the overall score for each category